PFE
Pfizer Inc.
Stock$25.34
+$0.01 (+0.04%)
Current Price (API): $25.34About
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
Price History (Last 30 Days)
Latest News & Updates
Major pharmaceutical companies face a patent cliff with $175 billion in annual d...
Major pharmaceutical companies face a patent cliff with $175 billion in annual drug sales losing exclusivity over the next six years, prompting increased M&A activity. Two biotech ETFs—SPDR S&P Biotech (XBI) and iShares Biotechnology (IBB)—offer investors exposure to capitalize on industry volatility and potential winners from consolidation.
The article recommends three healthcare stocks poised to benefit from rising fed...
The article recommends three healthcare stocks poised to benefit from rising federal healthcare spending projected to exceed $3 trillion within a decade. Pfizer offers an attractive 6.5% dividend yield with a robust drug pipeline; Intuitive Surgical dominates robotic surgery with recurring revenue from instruments and servicing; and Eli Lilly is capitalizing on blockbuster GLP-1 weight-loss drugs with strong revenue growth.
Doximity stock fell 24% after reporting mixed Q4 2026 earnings with only 5% sale...
Doximity stock fell 24% after reporting mixed Q4 2026 earnings with only 5% sales growth and disappointing 2027 guidance of 3-5% revenue growth. The company is increasing AI spending amid a soft healthcare advertising market, pressuring profitability. Despite industry headwinds, Doximity maintains its market leadership with 85% of U.S. physicians on its platform and trades at a cheap 12x forward earnings valuation.
Eli Lilly dominates the rapidly growing weight loss drug market with its GLP-1 d...
Eli Lilly dominates the rapidly growing weight loss drug market with its GLP-1 drugs Mounjaro and Zepbound, generating over $12 billion in quarterly sales. The company recently launched Foundayo, an oral GLP-1 pill, which could cannibalize Zepbound sales but is more likely to expand the patient base by attracting new GLP-1 users. While Lilly faces competition from Novo Nordisk and other pharma companies, analysts view Foundayo as a growth opportunity rather than a threat.
A hantavirus outbreak on a cruise ship sparked a biotech rally, but the article...
A hantavirus outbreak on a cruise ship sparked a biotech rally, but the article argues investors should avoid jumping in. The hantavirus is less contagious than COVID-19 and unlikely to become a global pandemic, limiting vaccine market potential. Even if it does spread widely, predicting which companies will succeed is nearly impossible, as demonstrated by COVID-19 vaccine developers. Better opportunities exist in established vaccine makers with strong pipelines or broad market index funds.
The global colorectal cancer diagnostics and therapeutics market is projected to...
The global colorectal cancer diagnostics and therapeutics market is projected to grow from USD 35 billion in 2025 to USD 73 billion by 2034 at a CAGR of ~9%. Growth is driven by rising colorectal cancer prevalence, increased screening awareness, advancements in non-invasive diagnostics (liquid biopsy, stool-based DNA tests), and emerging targeted therapies and immunotherapies. North America leads with 41% market share, while Asia-Pacific is the fastest-growing region.
The article identifies three undervalued stocks facing current headwinds that co...
The article identifies three undervalued stocks facing current headwinds that could offer strong long-term returns: Duolingo (down 80% due to AI concerns but maintaining strong 38% profit margins), Pfizer (down 56% since 2022 due to patent cliffs but has 96 drug candidates in pipeline), and Robinhood Markets (down 30% this year due to weak crypto market but has growth opportunities in prediction markets).
Nurix Therapeutics announced that its CEO Arthur T. Sands will participate in fi...
Nurix Therapeutics announced that its CEO Arthur T. Sands will participate in fireside chats at the RBC Global Healthcare Conference (May 20, 2026) and Jefferies Global Healthcare Conference (June 3, 2026). The company is advancing targeted protein degradation medicines for oncology and autoimmune diseases, with clinical-stage programs including BTK degraders and CBL-B inhibitors, alongside partnerships with Sanofi, Gilead, and Pfizer.
Rigel Pharmaceuticals announced an exclusive global licensing agreement with Arv...
Rigel Pharmaceuticals announced an exclusive global licensing agreement with Arvinas and Pfizer for VEPPANU (vepdegestrant), an oral PROTAC drug for ER+/HER2- ESR1-mutated advanced or metastatic breast cancer. Rigel will contribute up to $40 million toward development over four years and pursue U.S. and global commercialization rights. The drug received FDA approval in May 2026, showing a 43% reduction in disease progression or death risk compared to fulvestrant in the Phase 3 VERITAC-2 trial.
Pfizer faces significant headwinds from patent cliffs on blockbuster drugs and d...
Pfizer faces significant headwinds from patent cliffs on blockbuster drugs and declining COVID-19 revenue, but is attempting to rebuild through oncology expansion and acquisitions like Seagen. Trading at less than 9x forward earnings with a 6%+ dividend yield, the stock is rated a 'hold' - a mature company in transition with moderate upside potential if its oncology strategy succeeds, but risks if revenue erosion outpaces pipeline growth.
